ALL Therapeutics

The impact of KMT2A rearrangements and allo-HSCT on survival outcomes in ALL

Acute lymphoblastic leukemia (ALL) with KMT2A rearrangements is classified as a high-risk genomic subtype of ALL. Multiple...

How are transplant options evolving for patients with ALL?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Aaron Logan, UCSF, San Francisco, US. We asked,...

Brexucabtagene autoleucel approved by the FDA for use in adult ALL

On October 1, 2021, brexucabtagene autoleucel (brexu-cel) became the first chimeric antigen receptor (CAR) T-cell therapy to be...

Does current reporting on CAR T-cell therapy in clinical trials overestimate efficacy? Why the distinction between ITT and mITT populations is important

Anti-CD19 chimeric antigen receptor (CAR)...

Omission of vincristine/dexamethasone pulse therapy does not adversely affect outcome in low-risk pediatric ALL

Additional pulses of vincristine (V) plus prednisone (Pred) or vincristine plus...

Is chemo-free ponatinib, venetoclax, and dexamethasone safe/effective in patients with R/R Ph+ ALL?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub...

FDA approval of ruxolitinib for the treatment of patients with chronic GvHD

On September 22, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of ruxolitinib for...

Use of ruxolitinib in patients with severe COVID-19

Colleagues from the RUXO-COVID Study Group have recently published the findings of a prospective observational study in Leukemia, in which they...